Skip to main content

LSBC Expands License for Gene Expression Technologies

NEW YORK, Dec. 4 – Proteomics and functional genomics company Large Scale Biology Corporation said Tuesday it had exercised an option to expand its deal with Plant Bioscience of Norwich, UK, to include all higher plants. 

In June, LSBC of Vacaville, Calif., licensed viral-derived gene silencing and overexpression technology from Plant Bioscience, an intellectual property management company that manages emerging technologies from academic institutions.

At the time of the original deal, LSBC said it would use the technology in conjunction with its Geneware plant viral vectors on a limited range of plants.

The expanded deal will now include the application of the technology for commercially relevant monocots in addition to dicots.

The expanded use of the PBL license "allows LSBC's patented Geneware functional genomics technology to include monocots as well as dicots as we introduce gene sequences rapidly into mature plants in just a matter of days, not months,” Guy della-Cioppa, LSBC vice president of business development, said in a statement. 

“We then study overexpression gain-of-function phenotypes or gene silencing loss-of-function phenotypes,” he added.

Financial terms of the deal were not disclosed.

The Scan

Gap in COVAX Doses

BBC News reports that COVAX is experiencing a vaccine shortfall, as the Serum Institute of India has paused exports.

Sanofi, GSK Report Promising Results

The Wall Street Journal reports that the candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline has had encouraging early results.

Influence of Luck

The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases.

PLOS Papers on Retina GWAS, Hantaan Virus, COVID-19 Phenome-Wide Association Study

In PLOS this week: genome-wide association study of retinal morphology, analysis of hantaan virus found in a mouse, and more.